eugenol | 110346-52-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: eugenol
• 英文别名: Phenol, 2-methoxy-4-(1-methylethenyl)-；2-methoxy-4-prop-1-en-2-ylphenol
• CAS: 110346-52-6
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.204
• InChiKey: UVMRYBDEERADNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  香草酸乙酯 生成 eugenol
  参考文献：
  名称：

  Behal; Tiffeneau, Bulletin de la Societe Chimique de France, 1908, vol. <4> 3, p. 730

  摘要：

  DOI：

文献信息

• IONIC LIQUID SYSTEMS
  申请人：The Procter & Gamble Company

  公开号：US20160177222A1

  公开（公告）日：2016-06-23

  The present invention relates to an ionic liquid system for enhanced delivery and/or deposition of a perfume raw material onto a substrate, particularly fabric, hard surfaces, soft surfaces, skin, or hair. The invention also relates to consumer products comprising the new ionic liquid systems, and processes for making and methods of using such ionic liquid systems and consumer products.

  本发明涉及一种离子液体系统，用于增强香水原料在基底上的传递和/或沉积，特别是织物、硬表面、软表面、皮肤或头发。该发明还涉及包含新离子液体系统的消费产品，以及制造和使用这种离子液体系统和消费产品的方法。
• Involvement of purinergic signalling in central mechanisms of body temperature regulation in rats
  作者：Alexander V Gourine、Ekaterina V Melenchuk、Dmitry M Poputnikov、Valery N Gourine、K Michael Spyer

  DOI：10.1038/sj.bjp.0704679

  日期：2002.4

  P2 purinoreceptors are present in hypothalamic and brainstem nuclei that are involved in the regulation of body temperature (Tb). The role of ATP acting on these P2 receptors in thermoregulation was investigated by studying the effects of the stable ATP analogue α,β‐methyleneATP (α,β‐meATP) and P2 receptor antagonists suramin and pyridoxal‐5′‐phosphate‐6‐azophenyl‐2′,4′‐disulphonic acid (PPADS) on Tb when injected intracerebroventricularly (i.c.v.) via a pre‐implanted cannula in conscious rats at various ambient temperatures and during lipopolysaccharide (LPS)‐induced fever. Depending on ambient temperature, α,β‐meATP (0.2 μmol, i.c.v.) induced a fall in Tb (−3.3°C, P<0.05), no changes in Tb when compared to pre‐injection levels, or an increase in Tb (∼1.0°C, P<0.05) in rats maintained at 10°C, 25°C and 30°C ambient temperature, respectively. Suramin (7 nmol, i.c.v.) induced a lasting (up to 6 h) increase in Tb (on average 1.2°C, P<0.05) in rats kept at 25°C or 30°C, but failed to induce any rise in Tb in rats at 10°C ambient temperature. An increase in Tb was also observed in rats (25°C ambient temperature) treated with PPADS (0.2 μmol, i.c.v.). α,β‐meATP (0.2 μmol) injected i.c.v. or directly into the anterior hypothalamus caused a profound fall in Tb (by 0.9°C and 1.0°C, respectively; P<0.05) during LPS (E.coli; 50 μg kg−1)‐induced fever in rats at 25°C ambient temperature. Fever was initiated more rapidly in rats treated with suramin (7 nmol) or PPADS (70 nmol), however its late phase was unaffected. Suramin (7 nmol) and PPADS (70 nmol) injected at the time when fever was already developed (2.5 h after LPS injections) did not alter febrile Tb. These data indicate that purinergic signalling may play a significant role in central mechanisms of Tb regulation at various ambient temperatures and during fever. British Journal of Pharmacology (2002) 135, 2047–2055; doi:10.1038/sj.bjp.0704679

  在下丘脑和脑干核中存在P2嘌呤受体，这些核团参与了体内温度调节（Tb）。研究了ATP作用于这些P2受体在体温调节中的作用，方法是通过预先植入的导管将稳定的ATP类似物α,β-甲基ATP（α,β-meATP）和P2受体拮抗剂suramin及吡哆醛-5′-磷酸-6-偶氮苯基-2′,4′-二磺酸（PPADS）直接注入清醒大鼠脑室内（i.c.v.），在不同环境温度下及脂多糖（LPS）诱导的发热过程中观察其对Tb的影响。根据环境温度的不同，α,β-meATP（0.2 μmol，i.c.v.）在分别维持在10°C、25°C和30°C环境温度的大鼠中，诱导Tb下降（-3.3°C，P < 0.05），或与注射前水平无变化，或Tb升高（约1.0°C，P < 0.05）。suramin（7 nmol，i.c.v.）在25°C或30°C环境下使Tb持续升高（平均升高1.2°C，P < 0.05），时间长达6小时；但在10°C环境温度下未能引起Tb升高。在25°C环境温度下PPADS（0.2 μmol，i.c.v.）处理的大鼠中也观察到了Tb升高。α,β-meATP（0.2 μmol）在i.c.v.或直接注入前下丘脑时，在25°C环境温度下E. coli（50 μg kg−1）诱导的发热大鼠模型中，引起明显的Tb下降（分别为0.9°C和1.0°C，P < 0.05）。接受suramin（7 nmol）或PPADS（70 nmol）处理的动物，发热启动更快，但其发热的后期阶段不受影响。当在发热已经发生（LPS注射后2.5小时）时给予suramin（7 nmol）或PPADS（70 nmol），则未改变发热状态下的Tb。这些数据表明，嘌呤信号传递可能在各种环境温度下及发热过程中的体温调节中枢机制中发挥重要作用。英国药理学杂志 (2002) 135, 2047–2055; doi:10.1038/sj.bjp.0704679
• IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS
  申请人：GIVAUDAN SA

  公开号：US20170297992A1

  公开（公告）日：2017-10-19

  A fragrance precursor of 3-(4-isobutyl-2-methyl phenyl)propanal, comprising at least an enamine and/or an aminal as reaction product of 3-(4-isobutyl-2-methylphenyl)propanal (compound according to formula (I)) and a primary and/or secondary amine useful as a perfume ingredient.

  一种3-(4-异丁基-2-甲基苯基)丙醛的香气前体，包括至少一种烯胺和/或氨缩醛，作为3-(4-异丁基-2-甲基苯基)丙醛（化合物式（I）所示的化合物）和初级和/或二级胺的反应产物，可作为香料成分。
• ENCAPSULATES
  申请人：The Procter & Gamble Company

  公开号：EP2806018A1

  公开（公告）日：2014-11-26

  The present application relates processes that can be used to produce encapsulated benefit agents comprising a core and a shell that encapsulates said core, encapsulated benefit agents produced by such process and products comprising such encapsulated benefit agents as well as methods of making and using such products. Such process can be used to produce particles that offer the desired protection and release benefits when used in a varity of products.

  本申请涉及可用于生产由核心和封装所述核心的外壳组成的胶囊化益处剂的工艺、由此类工艺生产的胶囊化益处剂和包含此类胶囊化益处剂的产品以及制造和使用此类产品的方法。这种工艺可用于生产在各种产品中使用时能提供所需的保护和释放益处的颗粒。
• Compositions comprising encapsulated actives within droplets and other compartments
  申请人：The Procter & Gamble Company

  公开号：US10434485B2

  公开（公告）日：2019-10-08

  The present invention generally relates to microparticles and, in particular, to systems and methods for encapsulation within microparticles. In one aspect, the present invention is generally directed to microparticles containing entities therein, where the entities contain an agent that can be released from the microparticles, e.g., via diffusion. In some cases, the agent may be released from the microparticles without disruption of the microparticles. The entities may be, for instance, polymeric particles, hydrogel particles, droplets of fluid, etc. The entities may be contained within a fluid that is, in turn, encapsulated within the microparticle. The agent may be released from the entity into the fluid, and then from the fluid through the microparticle. In such fashion, the release of agent from the microparticle may be controlled, e.g., over relatively long time scales. Other embodiments of the present invention are generally directed to methods of making such microparticles, methods of using such microparticles, microfluidic devices for making such microparticles, and the like.

  本发明一般涉及微粒，特别是涉及在微粒内封装的系统和方法。在一个方面，本发明一般针对其中含有实体的微粒，实体中含有可通过扩散等方式从微粒中释放的药剂。在某些情况下，药剂可以在不破坏微颗粒的情况下从微颗粒中释放出来。实体可以是聚合物颗粒、水凝胶颗粒、液滴等。实体可以包含在流体中，而流体又封装在微粒中。药剂可以从实体释放到流体中，然后通过微粒从流体中释放出来。通过这种方式，可以控制药剂从微粒子中的释放，例如在相对较长的时间范围内。本发明的其它实施方案一般针对制造此类微粒的方法、使用此类微粒的方法、制造此类微粒的微流体设备等。